Upload
vodang
View
214
Download
0
Embed Size (px)
Citation preview
The global marine pharmaceutical i lipipeline
Alejandro M. S. Mayer, Ph.D.
Midwestern University Pharmacology Department, CCOM
Downers Grove Illinois USADowners Grove, Illinois, USA
1
The global marine pharmaceutical pipeline
FDA d i h i l• FDA- approved marine pharmaceuticals• The Clinical Pipelinep• The Preclinical Pipeline
http://marinepharmacology.midwestern.edu/
3
FDA –approved: 7
Clinical Pipeline: 11
Preclinical Pipeline: 1,458
Chemistry Marine Natural Products: 8,940
5Global Marine Pharmaceutical Pipeline in 2012
The global marine pharmaceutical pipeline
• FDA- approved marine pharmaceuticalspp p• The Clinical Pipeline• The Preclinical Pipelinep
• The Odyssey of Marine Pharmaceuticals: aThe Odyssey of Marine Pharmaceuticals: a Current Pipeline Perspective, Trend in Pharmacological Sciences, 31: 255-265, 2010
6
Cytarabine Ara C (Cytosar): FDA approval 1969Cytarabine, Ara-C (Cytosar): FDA approval 1969
Arabinosylcytosine or cytosine
arabinoside is a synthetic pyrimidine
Caribbean sponge Tethya crypta, source of spongothymidine, led to synthesis of new class of arabinosyl
8
synthetic pyrimidine nucleoside
synthesis of new class of arabinosyl nucleosides.
Cytarabine Ara C (Cytosar): CancerCytarabine, Ara-C (Cytosar): Cancer
• Pharmacology: cytosine arabinoside is rapidly converted into cytosine arabinoside triphosphate, which inhibits the DNA polymerase by competing with the physiologic substrate deoxycitidine triphosphatetriphosphate
• Indications for use: induction and maintenance of remission in acute non lymphocytic leukemia ofremission in acute non-lymphocytic leukemia of adults and children
Al d f t l h ti l k i d• Also used for: acute lymphocytic leukemia and chronic myelocytic leukemia
9
Cytarabine, Ara-C (Cytosar): Hospira, USA
11Downloaded from http://www.hospira.com/Products/cytarabine.aspx
Vidarabine Ara A (Vira A): FDA approval 1976Vidarabine, Ara-A (Vira-A): FDA approval 1976
ArabinofuranosyladenineArabinofuranosyladenine or adenine arabinoside is
a synthetic purine Caribbean sponge Tethya crypta, source of spongouridine, led to
th i f l f bi l12
nucleoside synthesis of new class of arabinosyl nucleosides.
Vidarabine Ara A (Vira A): AntiviralVidarabine, Ara-A (Vira-A): Antiviral
Ph l Vid bi i t d i t bi id• Pharmacology: Vidarabine is converted into arabinoside triphosphate, and inhibits viral DNA polymerase and DNA synthesisDNA synthesis
• Indications for use: 3% ophthalmic ointment is used for t k t j ti iti d t ith li lacute keratoconjunctivitis and recurrent epithelial
keratitis, caused by herpes simplex virus types 1 and 2C tl di ti d i th U S t d i FDA• Currently discontinued in the U.S. as noted in FDA Orange Book (3-2011)
13
Ziconotide (Prialt): FDA approval 2004Ziconotide (Prialt): FDA approval 2004
25 amino acid, polybasic peptide containing 3
Piscivorous marine snail Conus magus, source of the naturally occurring conopeptidepeptide containing 3
disulfide bridges and the FDA-approved drug
of the naturally occurring conopeptide
• Developed as a pain medication
15
pp gPrialt®
Omega 3 acid Ethyl Ester (Lovaza): FDA approval 2004Omega-3-acid Ethyl Ester (Lovaza): FDA approval 2004
ethyl esters of eicosapentaenoic acid (EPA) ethyl esters of docosahexaenoic acid (DHA)
18
Downloaded from http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021654s023lbl.pdf
Omega-3-acid Ethyl Esters (Lovaza): GlaxoSmithKline, UK
20Downloaded from http://www.gsk.com/products/prescription-medicines/lovaza.htm
Trabectedin, ET-743 (Yondelis®): cancer
Colonial ascidian Ecteinascidia turbinata(Phylum Chordata, Subphylum: Urochordata)
150
200175 PubMed 2000-07
50
100Pharmacology
Binds to the minor groove of DNA and interferes with cell division and the gene
21
2000
2001
2002
2003
2004
2005
2006
2007
0
interferes with cell division and the gene transcription processes and repair machinery of the DNA.
Trabectedin, ET-743 (Yondelis®): FDA approval 2005
22http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/default.htm
Trabectedin, ET-743 (Yondelis®): FDA approval 2005( ) pp
Downloaded from
23
Downloaded fromhttp://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm
Trabectedin, ET-743 (Yondelis®): Pharmamar, Spain
25Downloaded from http://www.pharmamar.com/yondelis.aspx
Eribulin mesylate (Halaven®) : FDA approval 2010
Halichondrin B analogue E7389 Sponge Lissodendoryx sp. (Ph l P if ) C t f J h Bl t
g(macrolide, polyketide)
Pharmacology
(Phylum:Porifera) Courtesy of John Blunt, Univ. of Canterbury, N. Zealand
• Microtubule interacting agent
• Developed as an anticancer agent
• Developed by Eisai, Woodcliff Lake, NJ
26
Eribulin mesylate (Halaven®): Eisai Co., Ltd, Japan
28
Downloaded from http://www.eisai.com/pdf/eir/epipeline.pdf
Brentuximab vedotin : FDA approval 2011
H2
HN
NN
O
NH
HO
N OMeO O HOMe O
Monomethyl Auristatin E (peptide)
Dolabella auricularia (sea hare)
Phylum: Mollusca, Class: Gastropoda
Monomethyl auristatin E (MMAE) is a synthetic anticancer agent Because of its toxicity it cannot beanticancer agent. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked to a monoclonal antibody (MAB) which directs it to the cancer cells.
29http://www.youtube.com/watch?v=WYuBjfJP84c
Brentuximab vedotin (SGN-35): cancer
H2N
HN
NN
OMeO
O
ONH
HO
OMe OmAb-linker-
Monomethyl Auristatin E (peptide)Anti-CD30-Seattle Genetics’ proprietary technology
Pharmacology
• Brentuximab vedotin is an antibody-drug conjugate (ADC) that targets CD30, a marker of Hodgkin lymphomamarker of Hodgkin lymphoma. • The ADC is stable in the bloodstream, but releases MMAE, an antimicrotubule agent, upon internalization into CD30-expressing tumor cells, resulting in a targeted cell-killing effect.
30Downloaded from http://www.seagen.com/product_pipeline_sgn35.shtml
Brentuximab vedotin (SGN-35): Seattle Genetics, USA
32Downloaded from http://www.seagen.com/product_pipeline.php
The global marine pharmaceutical pipeline
• FDA- approved marine pharmaceuticalsFDA approved marine pharmaceuticals• The Clinical Pipeline• The Preclinical Pipeline
33
FDA –approved: 7
Clinical Pipeline: 11
Preclinical Pipeline: 1,458
Chemistry Marine Natural Products: 8,940
Global Marine Pharmaceutical Pipeline in 201235
Global Marine Pharmaceutical Pipeline in 2012
Marine pharmaceuticals in Phase 3Marine pharmaceuticals in Phase 3
http://marinepharmacology midwestern edu/clinPipeline htmhttp://marinepharmacology.midwestern.edu/clinPipeline.htm
36
Plitidepsin (Aplidin®): Phase 3, cancer
OOCH3
N
ONH O
O
ONCH3
ONCH3O
Aplidium albicans (seasquirt)O
ONH
OH
ONH
N
ON
OO
O
Plitidepsin (depsipeptide)p ( q )
(Phylum Chordata, Subphylum:Tunicata)
Pharmacology
• Extremely potent inducer of apoptosis with IC50 in the low nanomolarExtremely potent inducer of apoptosis with IC50 in the low nanomolar range. • It triggers Rac 1 activation, together with MPK-1 downregulation, and sustained JNK activation.
O i ff t k t id tif th i ll l t t37
• Ongoing efforts seek to identify the primary cellular target.
Mayer et al. TIPS 2010
PM00104 (Zalypsis®): Phase 2, cancer
CH3
OCH3
AcOHO
H3CCH3
AcO
NN
OHO
O
H
CF3
OHONH
O Jorunna funebris (sea slug)(Phylum: Mollusca Class: Gastropoda)
Pharmacology(Zalypsis®) alkaloid
(Phylum: Mollusca, Class: Gastropoda)
• New DNA-binding alkaloid isolated from the skin and mucus of the Pacific nudibranch Joruna funebris.
• Zalypsis® binds to guanines in selected DNA triplets, DNA adducts eventually give rise to double strand breaks, S-phase arrest and apoptosis in cancer cells.
41Mayer et al. TIPS 2010
Glembatumumab vedotin (CDX-011) : Phase 2, cancer
H2
HN
NN
O
NH
HO
N OMeO O HOMe O
Monomethyl Auristatin E (peptide)
Dolabella auricularia (sea hare)
Phylum: Mollusca, Class: Gastropoda
Monomethyl auristatin E (MMAE) is a synthetic anticancer agent Because of its toxicity it cannot beanticancer agent. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked to a monoclonal antibody (MAB) which directs it to the cancer cells.
44
Glembatumumab vedotin (CDX-011) : Phase 2, cancer
H2N
HN
NN
OMeO
O
ONH
HO
OMe OmAb-linker-
Monomethyl Auristatin E (peptide)Anti-NMB-Seattle Genetics’ proprietary technology
Pharmacology
• Brentuximab vedotin is an antibody-drug conjugate (ADC) that targets glycoprotein NMB a marker of breast cancerglycoprotein NMB, a marker of breast cancer. • The ADC is stable in the bloodstream, but releases MMAE, an antimicrotubule agent, upon internalization into NMB-expressing tumor cells, resulting in a targeted cell-killing effect.
45Downloaded from http://www.celldextherapeutics.com/wt/page/cancer
Glembatumumab vedotin: CellDex Therapeutics, USA
Downloaded from http://www celldextherapeutics com/wt/page/pipeline redirect
47
Downloaded from http://www.celldextherapeutics.com/wt/page/pipeline_redirect
Marizomib (Salinosporamide A): Phase 1, Cancer
OHH
HN
O
O
OO
CH3
Salinosporamide A is a beta-lactone-gamma-lactam
Salinospora tropica, a marine bacteria (Phylum: Actinobacteria). Courtesy of Ray Lam,
Cl
lactone gamma lactam
Pharmacology Preclinical and Clinical research
Nereus Pharmaceuticals
gy• Covalent modification of the active site threonine residues of the 20S proteasome a multi-
• Developed as an Anticancer agent
• Developed by Nereus Pharmaceuticals,
49
the 20S proteasome, a multisubunit enzyme complex that degrades ubiquitin-tagged proteins in eukaryotic cells
San Diego, CA
Salinosporamide A (NPI-0052): Nereus, USA
51Downloaded from http://www.nereuspharm.com/overview.shtml
The global marine pharmaceutical pipelineThe global marine pharmaceutical pipeline
• FDA- approved marine pharmaceuticalsFDA approved marine pharmaceuticals• The Clinical Pipeline• The Preclinical Pipeline
52
FDA –approved: 7
Clinical Pipeline: 11
Preclinical Pipeline: 1,458
Chemistry Marine Natural Products: 8,940
Global Marine Pharmaceutical Pipeline in 2012
Marine pharmaceutical preclinicalpipeline
• For the period 1998-2008• 13 marine pharmacology reviews• 1,458 compoundsp• Global research enterprise• Multiple pharmacological classesMultiple pharmacological classes
55
The global marine pharmaceutical preclinical pipeline
56Global research involving investigators in 32 countries & US in the period 2007-2008
Marine pharmaceutical preclinicalpipeline
• For the period 1998-2008• 13 marine pharmacology reviews• 1,458 compoundsp• Global research enterprise• Multiple pharmacological classesMultiple pharmacological classes
57
The marine pharmaceuticals preclinical pipeline in 2007-2008: 197 compounds
• Antitumor• Antibacterial
• Anticoagulant • Cardiovascular
• Antifungal• Antiviral
• Anti-inflammatory• Immune system
• Antimalarial• Antituberculosis
• Nervous system• Variety of molecular
• Antiprotozoal targets: eg. enzymes, receptors
58
The global marine pharmaceutical pipeline: conclusionsThe global marine pharmaceutical pipeline: conclusions
Bi di it f i i d h i t• Biodiversity of marine organisms and chemistry• FDA-approved agents in several therapeutic areas• Active clinical pipeline: Phase 1, 2, 3• Biotechnology: FDA-approved, Phase 1 & 2 MABs • Preclinical pipeline could be larger if $$ increases• US, European & Japanese companies involvedUS, European & Japanese companies involved• Large markets for pharmaceuticals in cancer, etc.
60
AcknowledgementsGlobal Marine Pharmaceutical Clinical Pipeline:• J. Michael Macintosh, M.D., University of Utah• David Newman, Ph.D., National Cancer Institute• Keith Glaser, Ph.D., Abbott Laboratories• Robert Jacobs, Ph.D., U.C. Santa Barbara, ,• Daniel Little, Ph.D., U.C. Santa Barbara• William Kem, Ph.D., University of Florida• Barbara Potts Ph D Nereus Pharmaceuticals• Barbara Potts, Ph.D., Nereus Pharmaceuticals• Dale Shuster, Ph.D., Eisai Pharmaceuticals• Maria del Carmen Cuevas Marchante, Ph.D., PharMamar, Spain
Global Marine Pharmaceutical Preclinical Pipeline reviews• Roberto Berlinck, Ph.D., University of Sao Paulo. Brasil, , y• Mark Hamann, Ph.D., University of Mississippi, USA • Abimael Rodriguez, Ph.D., University of Puerto Rico, USA• Nobuhiro Fusetani Ph D Hokkaido University Japan
61
• Nobuhiro Fusetani, Ph.D., Hokkaido University, Japan• Kirk Gustafson, Ph.D., National Cancer Institute, USA
New developments in the marine pharmaceutical clinical and preclinical
pipeline will be posted @pipeline will be posted @
htt // i h l id t dhttp://marinepharmacology.midwestern.edu/
62